Sohan Dua, MD
Nephrology · Northridge, CANPI 1174545693
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 72.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,671 and has fallen 96.6% since, to $56 in 2025.
Across 22 payments — averaging $98.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- Vifor Pharma, Inc.$200
- Otsuka America Pharmaceutical, Inc.$113
- Akebia Therapeutics Inc$84
- Amgen$71
- Novo Nordisk$55
- plus $77 from 2 others
Across 1,239 payments — averaging $2582.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$1.4M
- Grifols, S.A.$788K
- AbbVie$447K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$165K
- Gilead$152K
- Sanofi US Services Inc.$79K
- plus $134K from 4 others
What the payments were for
- Speaking & faculty fees$2009%
- Travel & lodging$1,14653%
- Food & beverage$78636%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,564 |
| Vifor Pharma, Inc. | 1 | $200 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Akebia Therapeutics Inc | 4 | $84 |
| Amgen | 3 | $71 |
| Novo Nordisk | 2 | $55 |
| GSK | 2 | $50 |
| Novartis | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
How this compares
$2,164 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $7,037 |
| Atorvastatin Calcium | 57 | $745 |
| Omeprazole | 16 | $388 |
| Levothyroxine Sodium | 29 | $315 |
| Pantoprazole Sodium | 11 | $305 |
| Metformin Hcl | 38 | $238 |
| Tamsulosin Hcl | 15 | $192 |
| Metoprolol Succinate | 14 | $156 |
| Amlodipine Besylate | 18 | $135 |
| Hydralazine Hcl | 12 | $121 |
| Allopurinol | 11 | $119 |
| Glipizide | 17 | $90 |
| Carvedilol | 12 | $59 |
| Simvastatin | 12 | $57 |
| Glimepiride | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Northridge
- Ramanath DukkipatiNorthridge$70K
- William YangNorthridge$66K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.